BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 24,000 Shares of Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 24,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 7th. The stock was sold at an average price of $95.86, for a total value of $2,300,640.00. Following the sale, the chief executive officer directly owned 63,209 shares in the company, valued at $6,059,214.74. This trade represents a 27.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Tuesday, October 6th, Ugur Sahin sold 21,000 shares of BioNTech stock. The shares were sold at an average price of $96.81, for a total value of $2,033,010.00.
• On Monday, October 5th, Ugur Sahin sold 72,000 shares of BioNTech stock. The shares were sold at an average price of $97.23, for a total value of $7,000,560.00.
• On Thursday, October 1st, Ugur Sahin sold 17,000 shares of BioNTech stock. The stock was sold at an average price of $97.46, for a total value of $1,656,820.00.
• On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The stock was sold at an average price of $98.12, for a total value of $3,139,840.00.
• On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.47, for a total value of $3,347,980.00.
• On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The stock was sold at an average price of $98.69, for a total value of $2,664,630.00.
• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The stock was sold at an average price of $98.99, for a total transaction of $3,860,610.00.
• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $99.40, for a total transaction of $2,982,000.00.
• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The shares were sold at an average price of $100.72, for a total transaction of $4,633,120.00.
• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The shares were sold at an average price of $97.81, for a total transaction of $3,227,730.00.

BioNTech Price Performance

Shares of BNTX stock traded down $0.48 during trading hours on Wednesday, hitting $95.25. The company’s stock had a trading volume of 827,996 shares, compared to its average volume of 1,087,206. The business has a fifty day moving average of $99.01 and a 200-day moving average of $95.10. The stock has a market cap of $24.09 billion, a price-to-earnings ratio of -12.16 and a beta of 1.25. BioNTech SE Sponsored ADR has a twelve month low of $79.52 and a twelve month high of $124.00. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The company had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. During the same quarter in the prior year, the firm earned ($1.60) earnings per share. The company’s revenue for the quarter was down 59.5% on a year-over-year basis. As a group, equities research analysts anticipate that BioNTech SE Sponsored ADR will post -6.37 EPS for the current year.

Analysts Set New Price Targets

BNTX has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a research note on Friday. BMO Capital Markets cut shares of BioNTech from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $128.00 to $105.00 in a research note on Tuesday, September 8th. Berenberg Bank set a $140.00 price target on shares of BioNTech in a report on Wednesday, September 16th. UBS Group reissued a “buy” rating on shares of BioNTech in a research report on Wednesday, September 16th. Finally, Canaccord Genuity Group reduced their price objective on shares of BioNTech from $142.00 to $136.00 and set a “buy” rating on the stock in a research note on Monday, August 31st. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, BioNTech has an average rating of “Moderate Buy” and a consensus target price of $125.69.

Institutional Trading of BioNTech

Hedge funds have recently added to or reduced their stakes in the business. Hsbc Holdings PLC purchased a new position in shares of BioNTech during the 4th quarter worth about $4,969,000. Bank of America Corp DE grew its holdings in BioNTech by 22.6% in the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock valued at $80,261,000 after purchasing an additional 166,432 shares during the period. Amundi grew its holdings in BioNTech by 24.5% in the first quarter. Amundi now owns 129,513 shares of the company’s stock valued at $11,511,000 after purchasing an additional 25,506 shares during the period. Headlands Technologies LLC acquired a new position in BioNTech during the second quarter worth approximately $2,520,000. Finally, Flossbach Von Storch SE acquired a new position in BioNTech during the second quarter worth approximately $207,142,000. 15.52% of the stock is owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.